Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/43777
Title: STRIDER NZAus: A multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction.
Authors: Groom, KM
Mccowan, LM
Mackay, LK
Lee, AC
Gardener, G
Unterscheider, J
Sekar, R
Dickinson, JE
Muller, P
Reid, RA
Watson, D
Welsh, A
Marlow, J
Walker, SP
Hyett, J
Morris, J
Stone, PR
Baker, PN
First Published: 19-Feb-2019
Publisher: Wiley, Royal College of Ostetricians and Gynaecologist (RCOG)
Citation: BJOG: An International Journal of Obstetrics and Gynaecology, 2019
Abstract: OBJECTIVE: To assess the effect of maternal sildenafil therapy on fetal growth in pregnancies with early-onset fetal growth restriction. DESIGN: A randomised placebo-controlled trial. SETTING: Thirteen maternal-fetal medicine units across New Zealand and Australia. POPULATION: Women with singleton pregnancies affected by fetal growth restriction at 22+0 to 29+6 weeks. METHODS: Women were randomised to oral 25mg sildenafil citrate or visually matching placebo three times daily until 32+0 weeks, birth or fetal death (whichever occurred first). MAIN OUTCOME MEASURES: The primary outcome was the proportion of pregnancies with an increase in fetal growth velocity. Secondary outcomes included livebirth, survival to hospital discharge free of major neonatal morbidity and preeclampsia. RESULTS: Sildenafil did not affect the proportion of pregnancies with an increase in fetal growth velocity; 32/61 (52.5%) sildenafil-treated 39/57 (68.4%) placebo-treated, adjusted OR 0.49, 95% CI 0.23-1.05 and had no effect on abdominal circumference Z-scores (p=0.61). Sildenafil use was associated with a lower mean uterine pulsatility index after 48 hours treatment (1.56 vs 1.81 p=0.02). The livebirth rate was 56/63 (88.9%) sildenafil-treated 47/59 (79.7%) placebo-treated, adjusted OR 2.50 (95%CI 0.80-7.79); survival to hospital discharge free of major neonatal morbidity was 42/63 (66.7%) sildenafil-treated 33/59 (55.9%) placebo-treated, adjusted OR 1.93 (0.84-4.45); and new-onset preeclampsia was 9/51 (17.7%) sildenafil-treated and 14/55 (25.5%) placebo-treated, OR 0.67 (95%CI 0.26-1.75). CONCLUSIONS: Maternal sildenafil use had no effect on fetal growth velocity. Prospectively planned meta-analyses will determine whether sildenafil exerts other effects on maternal and fetal/neonatal wellbeing.
DOI Link: 10.1111/1471-0528.15658
eISSN: 1471-0528
Links: https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.15658
http://hdl.handle.net/2381/43777
Embargo on file until: 19-Feb-2020
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2019, Wiley, Royal College of Ostetricians and Gynaecologist (RCOG). Deposited with reference to the publisher’s open access archiving policy. (http://www.rioxx.net/licenses/all-rights-reserved)
Description: The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.
Appears in Collections:Published Articles, College of Medicine, Biological Sciences and Psychology

Files in This Item:
File Description SizeFormat 
Appendix S1 21Jan19.docxPost-review (final submitted author manuscript)17.34 kBUnknownView/Open
STRIDER NZAus_Manuscript_21Jan2019.docxPost-review (final submitted author manuscript)157.48 kBUnknownView/Open
Figure 1 BJOG 21Jan2019.docxPost-review (final submitted author manuscript)30.06 kBUnknownView/Open
STRIDER+NZAus_Manuscript_21Jan2019.pdfPost-review (final submitted author manuscript)425.49 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.